SNCA and Parkinson disease: These observations along with studies demonstrating α-synuclein is processed by lysosomes in cell models overexpressing LRRK2 (Hu et al., 2018; Obergasteiger et al., 2019), underline the prospects of targetting lysosomal function as novel drug-developing avenues worth pursuing for LRRK2-related PD.